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Abstract
Background: Exertional dyspnea is the most prominent and disabling feature in idiopathic pulmonary fibrosis (IPF). 
The Medical Research Chronic (MRC) chronic dyspnea score as well as physiological measurements obtained during 
cardiopulmonary exercise testing (CPET) and the 6-minute walk test (6MWT) are shown to provide information on the 
severity and survival of disease.
Methods: We prospectively recruited IPF patients and examined the relationship between the MRC score and either 
CPET or 6MWT parameters known to reflect physiologic derangements limiting exercise capacity in IPF patients
Results: Twenty-five patients with IPF were included in the study. Significant correlations were found between the 
MRC score and the distance (r = -.781, p < 0.001), the SPO2 at the initiation and the end (r = -.542, p = 0.005 and r = -
.713, p < 0.001 respectively) and the desaturation index (r = .634, p = 0.001) for the 6MWT; the MRC score and VO2 peak/
kg (r = -.731, p < 0.001), SPO2 at peak exercise (r = -. 682, p < 0.001), VE/VCO2 slope (r = .731, p < 0.001), VE/VCO2 at AT (r 
= .630, p = 0.002) and the Borg scale at peak exercise (r = .50, p = 0.01) for the CPET. In multiple logistic regression 
analysis, the only variable independently related to the MRC is the distance walked at the 6MWT.
Conclusion: In this population of IPF patients a good correlation was found between the MRC chronic dyspnoea score 
and physiological parameters obtained during maximal and submaximal exercise testing known to reflect ventilatory 
impairment and exercise limitation as well as disease severity and survival. This finding is described for the first time in 
the literature in this group of patients as far as we know and could explain why a simple chronic dyspnea score 
provides reliable prognostic information on IPF.
Background
In idiopathic pulmonary fibrosis (IPF), the combination
of inflammatory and fibrotic lung parenchymal damage
adversely affects lung mechanics and gas exchange and
leads to progressive exertional breathlessness, the most
prominent and disabling symptom in these patients [1-4].
Additionally, pulmonary vascular derangements both
anatomic and functional [5,6] as well as myocardial dis-
turbances [7,8] and peripheral muscle weakness related
to the above changes [9,10] are all responsible for the pro-
gressive limitation in exercise capacity characteristically
observed in these patients who usually have a more rapid
an swallow breathing pattern [4,6,11-13].
Grading breathlessness with the aid of a variety of
chronic dyspnea scales is practice in the assessment of
IPF patients[14-17]. Recently, the Medical Research
Council (MRC) chronic dyspnea scale has been used by
several investigators including us, in the evaluation of dis-
ease severity in these patients[18,19]. The above men-
tioned studies have shown that the MRC score at the time
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of diagnosis may reflect severity and outcome[18-20].
Additionally, we have shown that that the MRC score sig-
nificantly correlates with the CD8+ T lymphocytes in both
tissue and bronchoalveolar lavage samples in these
patients, subpopulation of lymphocytes that may be
implicated in the pathogenesis of disease [21,22].
Previous studies have shown that physiological mea-
surements obtained during cardiopulmonary exercise
testing (CPET) [23] and the 6-minute walk test (6MWT)
[24] two of the most commonly used exercise protocols
may also provide information on the severity and out-
come of IPF [25,26] in an even more useful and reliable
way than resting physiological measurements such as
pulmonary function testing values and arterial blood
gases, in the prognostic evaluation of IPF patients [27-
32]. More precisely, CPET provides an accurate assess-
ment of abnormalities in the cardiovascular, respiratory,
metabolic, peripheral muscle and neurosensory systems,
under measured maximal physiological stress [23]. CPET
parameters such as peak oxygen consumption (VO2
peak), oxygen pulse, ΔPaO2/ΔVO2, the ventilatory equiva-
lent for carbon dioxide (VE/VCO2) at peak exercise and
PaO2 slope are found to be significant predictors of sur-
vival in IPF patients [15,33,34]. Furthermore, parameters
such as the distance walked and the level of desaturation
during the 6MWT, a practical inexpensive simple walking
test that examines submaximal levels of exertion, which
might better reflect daily physical activities, are also
found to be predictors of survival in this group of patients
[27-29].
In an effort to better understand why a simple chronic
dyspnea score, such as the MRC provides information on
the severity and survival of IPF patients, we hypothesized
that the MRC score could reflect physiologic derange-
ments limiting exercise capacity in IPF patients. We
tested our hypothesis by examining the potential rela-
tionship of the MRC score with well established and
quantifiable parameters of either cardiopulmonary exer-
cise testing or 6-minute walk test.
Methods
Subjects and Setting
This study was approved by the Institutional Ethics Com-
mittee of "Attikon" University Hospital, National and
Kapodistrian University of Athens, Greece. Written
informed consent was obtained from each patient. We
prospectively recruited patients examined at the outpa-
tient clinic over a period of one year. All patients fulfilled
the criteria of the American Thoracic Society, European
Respiratory Society and the American College of Chest
Physicians for the diagnosis of IPF: Abnormal pulmonary
function studies with evidence of restriction and
impaired gas exchange, bibasilar reticular abnormalities
with minimal ground glass opacities on high resolution
computerized tomography scans, transbronchial lung
biopsy or bronchoalveolar lavage showing no features to
support an alternative diagnosis, age older than 50 years,
insidious onset of otherwise unexplained dyspnea on
exertion, duration of illness more than 3 months, bibasi-
lar, inspiratory crackles (dry or "Velcro"-type in qual-
ity)[2,3]. Secondary causes of lung fibrosis were excluded:
none of the patients had a history of environmental or
occupational exposure, drug toxicity or autoimmune
rheumatic disease, as documented by history, clinical and
immunological tests. It is to be noted that the patients
included in the present study are different new patients
that have not been included in our previous studies
[18,20-22].
Dyspnea
Dyspnea was assessed at diagnosis by the treating physi-
cians (EDM, PL, CT) using the modified MRC chronic
dyspnea self-administered questionnaire consisting of six
questions about perceived breathlessness: 0, no dyspnea;
1, slight dyspnea (shortness of breath when hurrying on
the level or walking up a slight hill); 2, moderate dyspnea
(walks slower than people of the same age on the level
because of breathlessness); 3, moderately severe dyspnea
(stops because of breathlessness when walking at own
pace on the level); 4, severe dyspnea (stops for breath
after walking about 100 yards or after a few minutes on
the level); 5, very severe dyspnea (too breathless to leave
the house or breathless when dressing or undress-
ing)[18,19]. The Modified Borg Scale used at both the
6MWT and CPET is described as follows: 0, no breath-
lessness at all, 0.5 Very, very slight, just noticeable, 1 very
slight, 2 Slight breathlessness, 3 moderate, 4 some what
severe, 5 severe breathlessness, 6, 7 very severe breath-
lessness, 8, 9 very, very severe (almost maximum) and 10
maximum [16,17].
Pulmonary Functional Tests (PFTs)
Lung function tests were done at diagnosis or at an inter-
val not over passing 15 days at stable condition from the
realization of the 6MWT and the CPET. PFTs included
forced expiratory volume during the first second of expi-
ration (FEV1), forced vital capacity (FVC), total lung
capacity (TLC), and single-breath carbon monoxide dif-
fusing capacity (DLCO) all measured by MasterScreen
Body apparatus (Erich Jaeger GmbH, Wuerzburg, Ger-
many) Measurements were expressed as both percent of
predicted normal and as absolute values [35,36].
The 6 Minute Walk Test
The 6MWT test was done according to the ATS guide-
lines [24]. The test was performed along a measured cor-
ridor in our Department. Participants were encouragedManali et al. BMC Pulmonary Medicine 2010, 10:32
http://www.biomedcentral.com/1471-2466/10/32
Page 3 of 10
to cover as much distance as possible. The following data
were collected and analyzed: distance (meters), duration
(minutes), saturation at the initiation of the test, satura-
tion at the end of the test, pulse at initiation and at the
end of the test, the difference in saturation before and
after the test, blood pressure systolic and diastolic before
the test, Borg scale score before and after the test, age
(years), height (meters) and body weight (kilograms)
Cardiopulmonary Exercise Testing
The CPET was performed using a standardized protocol
in accordance with the American Thoracic Society/
American College of Chest Physicians (ATS/ACCP)
statement [23]. Patients were encouraged to take their
medication as usual. Patients taking beta blockers were
specifically excluded. On arrival at the exercise suite,
patients were connected to a 12-lead electrocardiogram
(Cardio Card, Oxycon Pro). Oxygen saturation was mea-
sured by digital pulse oxymetry (AutoCorr BCI) and
blood pressure by a sphygmomanometer. Calibration was
done according to the instructions of the manufacturers.
All patients underwent a maximal or symptom-limited
cardiopulmonary exercise test with an electromagneti-
cally braked cycle ergometer (Ergometrics 900, Erich Jae-
ger GmbH, Wurzburg, Germany) using a ramp protocol.
All tests were monitored continuously with three leads,
II, V1 and V5. The protocol included: 3 min of sitting rest,
3 min of unloaded cycling (at 60 revolutions per min. plus
or minus 5 revolutions per min.), followed by a progres-
sively increasing work rate (WR) in a ramp fashion and 3
min of recovery. The WR increment for each ramped
exercise test was individualized on the basis of each
patient's pretest activity level (range, 8 to 25 Watts/min).
The duration of the test was symptom-limited. Cardio-
pulmonary data were collected and analyzed with an
exercise metabolic unit (Oxycon Pro Erich Jaeger GmbH,
Wurzburg, Germany). The following parameters were
recorded: Heart rate (HR), minute ventilation (VE), tidal
volume (VT), peak oxygen consumption (VO2  peak),
peak oxygen consumption/Kg (VO2 peak/Kg), % VO2 pre-
dicted, VE/VCO2 slope, VE/VCO2 at AT, VT/IC, Borg
scale at peak exercise, respiratory rate (RR), total ventila-
tion (VE), oxygen pulse (O2P), oxygen saturation (SPO2),
anaerobic threshold (AT), breathing reserve (BR), Heart
rate recovery (HRR), Heart rate reserve (HRRes).
Statistical analysis
Data are presented as mean ± standard deviation. (± SD).
The non-parametric Spearman correlation coefficient
was calculated to describe the relationships between vari-
ables. A p-value less than 0.05 was considered significant.
Furthermore for variables that were significantly corre-
lated with MRC, simple logistic regression models were
fitted to identify predictors of MRC (separated in two cat-
egories, 0-2 and 3-4). Odds ratios (OR) and their 95%
confidence intervals were calculated. Variables significant
at 0.05 level were also entered in multiple stepwise logis-
tic regression analysis to examine their independent
effect on MRC groups. Statistical analyses were done
using SPSS v.13.0.0 (Chicago, IL).
Results
The population studied consisted of 25 patients with clin-
ical and radiological features of IPF. The demographic
and clinical characteristics of the study population at the
time of IPF diagnosis are given in detail in Table 1. Seven-
teen patients were male with a mean age of 67.5 years (±
8.3). Only one patient was a current smoker, the rest
being no smokers (44%) ex-smokers (52%) respectively.
Two patients had an MRC score of 0, eight a score of 1,
eight a score of 2, six a score of 3 and one a score of 4. No
patient included in the study had a score of 5. The results
of the PFTs are shown in Table 2. The study population
had a restrictive pattern with a mean value for FEV1/FVC
ratio, TLC and DLCO of 82.2% (± 4.5%), 61.4% (±
13.75%), and 45.6% (± 13.2%) respectively. Functional dif-
ferences between non smokers and ex-smokers were
examined and the only statistically significant difference
between groups was found for FVC% (p = 0.03). Table 3
summarizes the results of the 6MWT while Table 4 the
results of the CPET.
Selectively, the mean distance walked was 326.4 m (±
153.06), with a SatO2 at rest of 94.8% (±2.2%) and a SPO2
at the end of the 6MWT of 87.6% (± 5.6%). The mean
Table 1: Demographic and clinical data of the study 
population (n = 25)
Variables (n)
Age, year (n = 25) (mean ± SD) 67.5 (± 8.3)
Sex (M/F) (n = 25) 17/8
Smoking history
Ex smoker (n) % 13 (52%)
No smoker (n) % 11 (44%)
Smoker (n) % 1 (4%)
PY (mean ± SD) 25.4 (± 34.2)
MRC chronic dyspnea score
0.0 (n) % 2 (8%)
1.0 (n) % 8 (32%)
2.0 (n) % 8 (32%)
3.0 (n) % 6 (24%)
4.0 (n) % 1 (4%)
5.0 (n) % 0 (0%)
M/F Male/Female, PY Pack/yearsManali et al. BMC Pulmonary Medicine 2010, 10:32
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VO2 peak was 1233.3 ml/min (± 437.6), the VO2 peak/kg
15.5 ml/kg/min (± 3.9) and a % VO2 predicted 73.4% (±
19.1%). Four patients did not reach the anaerobic thresh-
old, while the mean values for VE/VCO2 slope, VE/VCO2
at anaerobic threshold and VT/IC were 40 (± 13.5), 41 (±
10.46) and 0.81 (± 0.14) respectively. The mean saturation
of oxygen at peak exercise was 87.7% (± 5.7%) and the
mean Borg scale for dyspnea at peak exercise was 4.84 (±
2.3). Out of 25 patients, 16 patients (64%) stopped CPET
due to mechanical constraint and the rest 9 (36%) due to
leg discomfort.
To examine our hypothesis, we studied whether the
MRC score at presentation was associated with any of the
parameters of the 6MWT and CPET performed at maxi-
mum 15 days interval from the initial evaluation of the
MRC at stable condition. The following correlations were
found:
Correlations between the MRC score and the parameters of 
the 6MWT
Statistically significant correlations were found between
the MRC score and the distance walked (r = -.781, p <
0.001), the SPO2 at the initiation and at the end of the test
(r = -.542, p = 0.005 and r = -.713, p < 0.001 respectively)
and the difference in saturation before and after the test (r
= .0634, p = 0.001) [Table 5, Figure 1] Correlations
between the MRC score and parameters of the 6MWT
such as the pulse at the initiation and at the end of the
test, the blood pressure, and the Borg dyspnea scale were
not found to be statistically significant.(data not shown)
Correlations between the MRC score and the parameters of 
the CPET
Statistically significant correlations were found between
the MRC score and the VO2 peak (r = -.496, p = 0.012),
the VO2 peak % (r = -.481, p = 0.017), the VO2 peak/kg (r
= -.731, p < 0.001), the saturation of oxygen at peak exer-
cise (r = -.682, p < 0.001), the BR peak% (r = -.437, p =
0.029), the VE/VCO2 slope (r = .731, p < 0.001), the HR
recovery (r = -.629, p = 0.001), the VE/VCO2 at AT (r =
0.630, p = 0.002) and the Borg scale at peak exercise (r =
0.5, p = 0.01) [Table 6, Figure 2, Figure 3]. Correlations
between the MRC score and parameters of the CPET
known to reflect restrictive mechanical constraint such as
the VE peak and the VT/IC were not found to be statisti-
cally significant. (Data not shown)
When applying simply logistic models for MRC catego-
ries [0-2 and 3-4] significant variables were found to be
the FEV1, the FVC, the TLC, the distance walked, the
VO2 peak, the VE/VCO2 slope and the VE/VCO2 at AT.
While when applying a multiple stepwise logistic regres-
sion analysis with these independent variables, the only
variable independently related to the MRC score with p <
0.05 is the distance walked at the 6MWT. (Data not
shown)
Discussion
In the present study we aimed to investigate for the first
time in the literature as far as we know why a simple, clin-
ical parameter such as the MRC chronic dyspnea score
reported by the patient provides information on the
severit y a nd su rvi va l of  IPF .  W e  h ypot hesized t ha t t he
MRC chronic dyspnea score mirrors one or multiple
physiologic derangements leading to exercise limitation.
Therefore the correlations between well established
quantifiable features of CPET and the 6MWT with the
MRC chronic dyspnea score at diagnosis were studied.
According to our results, the MRC dyspnea score is sig-
nificantly correlated with parameters such as the distance
walked and the desaturation index of the 6MWT and
with VO2 peak, the saturation of oxygen at peak exercise,
the BR peak%, the VE/VCO2 slope, the VE/VCO2 at AT,
Table 2: Pulmonary Function Test Parameters of the study population (n = 25)
Parameter n Mean (± SD)
FEV1 (Liters) 25 1.95 ± .51
FEV1% 25 80.4 ± 18.8
FVC (Liters) 25 2.4 ± .6
FVC% 25 77.5 ± 21.8
TLC (Liters) 23 3.5 ± .85
TLC% 23 61.4 ± 13.7
DLCO (mmol/min/kPa) 23 3.6 ± 1.4
DLCO% 23 45.6 ± 13.2
FEV1/FVC 25 .82 ± .04
FEV1 Forced expiratory volume at 1 second, % per cent, FVC Forced vital capacity, TLC Total Lung Capacity, DLCO Diffusion capacity for carbon 
monoxide, FEV1/FVC: FEV1/FVC ratioManali et al. BMC Pulmonary Medicine 2010, 10:32
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Table 3: Results of the 6 minute walk test (6MWT) in the study population (n = 25) in total as well as divided in groups 
based on the MRC score (0-1, 2, 3-4).
MRC
Total 0-1 2 3-4
N Mean SD N Mean SD N Mean SD N Mean SD
Distance 25 326.40 153.06 10 462.60 85.18 8 278.50 123.59 7 186.57 90.68
1SPO2 at the initiation % 25 94.84 2.23 10 96.60 1.51 8 93.63 1.51 7 93.71 2.29
1SPO2 at the end % 25 87.64 5.61 10 92.60 4.06 8 84.63 3.78 7 84.00 4.00
2DSPO2 25 7.20 4.29 10 4.00 3.89 8 9.00 3.55 7 9.71 2.75
PULSE at the initiation 25 80.16 13.75 10 76.00 13.46 8 83.00 17.21 7 82.86 9.53
PULSE at the end 24 104.25 17.15 9 105.89 18.59 8 102.75 19.89 7 103.86 14.09
3BP Systolic (mmHg) 25 123.60 12.71 10 128.00 8.88 8 119.38 14.74 7 122.14 14.68
3BP Diastolic (mmHg) 25 76.00 6.45 10 78.50 4.12 8 75.00 9.26 7 73.57 4.76
BORG scale at the initiation 25 0.18 0.35 10 0.10 0.32 8 0.19 .37 7 0.29 0.39
B O R G  s c a l e  a t  t h e  e n d 2 52 . 0 21 . 7 51 01 . 2 00 . 8 982 . 3 81 . 7 772 . 7 92 . 3 4
All values are shown as mean ± standard deviation (SD)
1 SPO2 oxygen saturation
2 DSPO2 Difference of saturation between the end and the initiation of the test
3 BP Blood pressure
the Borg scale at peak exercise and the HR recovery of the
CPET. Among all parameters of the 6MWT and the
CPET examined, the MRC score is shown to better and
independently reflect the distance walked at the 6MWT.
Furthermore, one third of the study population stopped
exercise during CPET due to leg discomfort and not to
mechanical constraint.
Dyspnea is a common and disabling symptom in IPF
patients. Many studies have been performed to under-
stand the pathophysiologic mechanisms underlying dysp-
nea in this group of patients in an effort to better and
effectively face this problem which significantly limits
functional capacity and quality of life. The MRC dyspnea
score has been used to grade breathlessness in patients
with IPF [18-22]. The present study shows that the MRC
score is strongly related to the parameters of the 6MWT
known to better predict severity and survival in IPF
patients, such as the desaturation to ≤88% and the dis-
tance walked. We found that the higher the MRC score
the shorter the distance walked and the lower the satura-
tion of oxygen at the end of the test. Very few data exist
on the literature concerning the relationship of the MRC
score and the 6MWT in IPF. In the study of Mura et al. no
correlation is found between the two, probably due to the
fact that almost one third of the study population pre-
sented with both IPF and emphysema, in contrast to our
patients which had no emphysema [37]. From a physio-
logic point of view our findings could be explained by the
fact that desaturation during exercise in IPF patients
reflects the overall impact of ventilation/perfusion mis-
matching, O2 diffusion limitation, low mixed venous PO2
and right to left intracardiac shunting in patients with a
more rapid and swallow breathing pattern[6]. Walking in
comparison to cycling recruits a wider range of muscle
groups and results in the perception of dyspnea in disease
states where oxygen delivery to peripheral muscles is lim-Manali et al. BMC Pulmonary Medicine 2010, 10:32
http://www.biomedcentral.com/1471-2466/10/32
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Table 4: Results of the cardiopulmonary exercise testing (CPET) in the study population (n = 25) in total as well as divided 
in groups based on the MRC score (0-1, 2, 3-4).
MRC
Total 0-1 2 3-4
N Mean SD N Mean SD N Mean SD N Mean SD
VO2 peak (ml/min) 25 1233.28 437.61 10 1391.80 305.87 8 1307.75 573.62 7 921.71 281.54
VO2 peak (%) 24 73.38 19.11 9 83.89 15.02 8 70.00 20.71 7 63.71 17.56
VO2 peak/kg (ml/kg/min) 25 15.46 3.90 10 18.38 2.68 8 14.49 3.24 7 12.41 3.40
AT (ml/kg/min) 21 11.57 3.48 10 12.97 2.68 5 11.36 2.95 6 9.42 4.36
Oxygen pulse (ml/beat) 25 9.19 2.83 10 10.16 2.31 8 9.51 3.36 7 7.44 2.35
Oxygen pulse (%) 24 78.17 22.62 9 92.22 23.69 8 70.25 14.27 7 69.14 22.36
SPO2 peak 25 87.72 5.68 10 93.00 3.62 8 84.00 3.30 7 84.43 4.39
VE peak (L/min) 25 54.20 17.52 10 56.20 15.82 8 54.50 19.26 7 51.00 20.03
VE peak (%) 24 78.08 19.72 9 75.89 17.07 8 72.50 15.43 7 87.29 26.01
BR peak % 25 27.32 21.18 10 36.00 17.96 8 25.75 22.18 7 16.71 21.82
VE/VCO2 25 40.00 13.52 10 29.00 6.32 8 43.13 12.03 7 52.14 10.75
HR reserve 25 19.20 17.99 10 20.20 22.11 8 19.00 17.17 7 18.00 14.62
HR recovery 25 14.48 8.30 10 19.39 5.76 8 13.25 10.48 7 8.86 4.34
VE/VCO2 at AT 21 41.00 10.46 10 35.10 3.84 5 39.20 7.66 6 52.33 11.71
VT/IC 25 0.81 0.14 10 0.82 0.15 8 0.82 0.07 7 0.80 0.21
Borg scale at peak 
exercise
25 4.84 2.30 10 3.00 1.83 8 6.75 1.17 7 5.29 1.98
All values are shown as mean ± standard deviation (SD)
VO2 peak oxygen uptake at peak exercise, AT anaerobic threshold, SPO2 oxygen saturation, VE peak minute ventilation at peak exercise, VE/VCO2 
slope: slope of relationship between VE and VCO2, HR Heart rate, VT tidal volume, IC Inspiratory capacity
ited. All the above mentioned derangements are mainly
related to the inability of the IPF patient to increase lung
volume and displace the thorax appropriately in the set-
ting of an increased ventilatory drive, leading to a sense of
breathing effort known as dyspnea and, as we speculate,
recapitulated by the MRC score in the present study
[6,10,38].
Among all parameters examined, the MRC score is
shown to better and independently reflect the distance
walked at the 6MWT. In the literature, this parameter is
considered highly reproducible and reliable as a measure-
ment compared to oxygen consumption and oxygen
desaturation that are associated with significant variation
in IPF patients [32]. Along with the desaturation of oxy-Manali et al. BMC Pulmonary Medicine 2010, 10:32
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gen, the distance walked is a significant predictor of sur-
vival[27,29]. The distance walked is known to be related
to patient effort, quadriceps strength and maximum
inspiratory pressure in COPD patients [39]. In IPF
patients, the distance walked is better correlated to func-
tional parameters as well as to the alveolar-arterial gradi-
ent for oxygen[37]. In our study population significant
correlation was not found between the MRC score and
the Borg scale at the end of 6MWT, but a significant cor-
relation was indeed found between the MRC score and
the Borg scale at peak exercise during CPET. The Borg
scale, a category scale with ratio properties, has been
shown to be reproducible and responsive and ideal for
the purpose of dyspnea assessment during CPET [6].
Such evidence does not exist for Borg Scale in 6MWT in
IPF patients. In the literature it is shown that although
desaturation is significantly more severe in IPF compared
to COPD, dyspnoea assessed with the Borg scale is signif-
icantly more severe in COPD [17]. This could explain
why this group of IPF patients with a significant desatura-
tion during the 6MWT but a moderate average Borg scale
walked a comparatively limited distance.
No study exists to our knowledge examining the rela-
tionship of the MRC score to CPET parameters in IPF.
We found that the MRC score is significantly related to
parameters reflecting ventilatory constraint such as the
VO2 peak, the VO2 peak/Kg, the saturation of oxygen at
peak exercise, the VE/VCO2 slope, VE/VCO2 at AT and
the Borg scale at peak exercise. The peak oxygen con-
sumption reflects the attainment of a limitation at some
point in the oxygen conductance pathway from the lungs
to the cytochrome-oxidase terminus of the electron
transport chain. Thus physiologic derangements of IPF
patients mentioned in the previous paragraph will be
reflected in abnormally low values of this parameter, as
w e l l  a s  o f  t h e  s a t u r a t i o n  o f  o x y g e n  a t  p e a k  e x e r c i s e
[40,41]. Concerning the VE/VCO2 slope, during CPET a
close linear relation exists between carbon dioxide and
minute ventilation. This relation is more linear and less
variable than that between oxygen and minute ventilation
and the slope can be used to describe ventilatory
response to exercise. In normal subjects the slope of VE/
VCO2 reflects that 23-25 liters of VE is required to elimi-
nate 1 liter of CO2 [21,40]. In our group of patients the
mean value (± SD) for VE/VCO2 slope was found at 40 (±
13.5). An abnormal VE/VCO2 slope (greater than 34) dur-
ing exercise has been suggested as an independent pre-
dictor of mortality in patients with chronic heart failure
and often as a correlate for advanced disease[42]. In IPF
patients, this parameter has not been extensively studied
but a steeper slope is related to associated reduced car-
diac output during exercise, increased pulmonary artery
and capillary wedge pressures, increased dead space/total
Table 5: Statistically significant relationships between the MRC chronic dyspnea score and the parameters of the 6 minute 
walk test (6MWT) in the study population quantified using Spearman's rank correlation coefficient
6MWT parameter MRC score
Distance r -.781
p <.001
SPO2 at initiation r -.542
p .005
SPO2 at the end r -.713
p <.001
DSPO2 r 0.634
p .001
SPO2 oxygen saturation, DSPO2 difference of saturation between the end and the initiation of the test, BP Blood pressure
Figure 1 The correlation between the MRC chronic dyspnea score 
and the distance in meters walked at the 6 minute walk test in the 
study population (n = 25) r = -.781, p < 0.001.Manali et al. BMC Pulmonary Medicine 2010, 10:32
http://www.biomedcentral.com/1471-2466/10/32
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volume ratio and increased respiratory drive leading thus
to more intense perception of dyspnea.
The prevalence of leg discomfort as the limiting factor
in IPF is unknown but it is likely to be significant [6]. One
third of our patients stopped exercise during CPET due
to leg discomfort and not to mechanical constraint.
The present study includes a homogeneous population
of IPF patients with demographic and functional charac-
teristics comparable to previous studies examining
6MWT and CPET determinants of the MRC chronic dys-
pnea scale as a prognostic tool in IPF [18,20,27,28,32,43].
However, limitations of this study consist first in the rela-
t ive l y s m a ll n u m ber  of  pa t ie n ts  a nd t o  t he  la ck  o f  IPF
patients with MRC score of 5. However in patients with
so high MRC scores, exercise is strongly limited leading
to early completion of exercise tests before the limits of
the pulmonary and cardiovascular systems are reached,
which could negatively influence the results of the study
Table 6: Statistically significant relationships between the MRC chronic dyspnea score and the parameters of the 
cardiopulmonary exercise testing (CPET) in the study population quantified using Spearman's rank correlation coefficient
CPET parameter MRC score
VO2 peak r -.496
p .012
VO2 peak % r -.481
p .017
VO2 peak/kg r -.731
p <.001
SPO2 peak r -.682
p <.001
BR peak % r -.437
p .029
VE/VCO2 slope r .731
p <0.001
HR recovery r -.629
p .001
VE/VCO2 at AT* r 0.630
p .002
Borg scale at peak exercise r 0.5
p .01
VO2 peak: oxygen uptake at peak exercise, AT anaerobic threshold, SPO2 oxygen saturation, VE peak: minute ventilation at peak exercise, VE/VCO2 
slope: slope of relationship between VE and VCO2, HR Heart rate, *VE/VCO2 at AT refers to 21 patients who reached AT
Figure 2 The correlation between the MRC chronic dyspnea score 
and the VE/VCO2 slope at cardiopulmonary exercise test in the 
study population (n = 25) r = .731, p < 0.001.
Figure 3 The correlation between the MRC chronic dyspnea score 
and the VE/VCO2 at anaerobic threshold (AT) at cardiopulmonary 
exercise test in the study population (n = 25) r = .63, p < 0.002.Manali et al. BMC Pulmonary Medicine 2010, 10:32
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[6]. Another limitation is the lack of information on the
cardiac performance and pulmonary hypertension status
of our patients, since data from heart ultrasounds are not
included in the analysis, despite the increasing impor-
tance of the impact of pulmonary hypertension on gas
exchange and exercise capacity in patients with pulmo-
nary fibrosis[44].
Conclusions
Based on the results of our study, the fact that the MRC
score predicts severity and outcome of IPF, could be
explained by the finding that the MRC score is related to
major functional parameters of both maximal and sub-
maximal exercise testing known to reflect ventilatory
impairment, exercise limitation and extent of disease and
found to be themselves highly prognostic of survival in
IPF. This finding is for the first time described in the liter-
ature as far as we know and could aid in the understand-
ing of exercise performance and limitation in this group
of patients.
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